Yan Leyfman: iVS-1 could be a promising next-gen Probiotic for those with Lactose Maldigestion
Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article on LinkedIn:
“New Study Alert!
A novel probiotic strain, Bifidobacterium adolescentis iVS-1, may help manage lactose intolerance by reducing gas, diarrhea, and urgency symptoms.
Isolated after GOS (prebiotic) consumption, iVS-1 showed high β-galactosidase activity and significantly improved GI symptoms in a 2-week RCT vs placebo.
Results:
- ↓ Gas formation.
- ↓ Diarrhea (p = 0.006).
- ↓ Fecal urgency (p = 0.033).
- ↑ Tolerance to lactose.
iVS-1 could be a promising next-gen probiotic for those with lactose maldigestion.”
Two-week supplementation of Bifidobacterium adolescentis iVS-1 reduces symptoms associated with lactose intolerance in lactose maldigesters.
Authors: Monica Ramakrishnan, Tzu-Wen L. Cross, Anna Clapp Organski, Sindusha Mysore Saiprasad, Abigayle M. R. Simpson, Daniel J. Tancredi, Mallory J. Van Haute, Chloe M. Christensen, Zachery T. Lewis, Thomas A. Auchtung, Jens Walter, Robert Hutkins, and Dennis A. Savaiano.
You can read the full article on Journal of Gut Microbes Reports.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023